AC Immune/$ACIU
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AC Immune
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
- Ticker
- $ACIU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 106
- Headquarters
- Lausanne, Switzerland
- Website
- www.acimmune.com
AC Immune Metrics
BasicAdvanced
$210M
-
-$0.43
-
-
Price and volume
Market cap
$210M
52-week high
$3.90
52-week low
$2.02
Average daily volume
216K
Financial strength
Current ratio
0.846
Quick ratio
0.233
Long term debt to equity
0.113
Total debt to equity
0.145
Interest coverage (TTM)
-166.53%
Profitability
EBITDA (TTM)
-44.604
Gross margin (TTM)
-184.83%
Net profit margin (TTM)
-181.95%
Operating margin (TTM)
-190.79%
Revenue per employee (TTM)
$232,630
Management effectiveness
Return on assets (TTM)
-15.20%
Return on equity (TTM)
-80.66%
Valuation
Price to revenue (TTM)
8.965
Price to book
5.27
Price to tangible book (TTM)
-6.05
Growth
Revenue change (TTM)
353.20%
Earnings per share change (TTM)
-51.47%
3-year revenue growth (CAGR)
2,605.98%
10-year revenue growth (CAGR)
-1.09%
3-year earnings per share growth (CAGR)
-24.55%
10-year earnings per share growth (CAGR)
7.67%
What the Analysts think about AC Immune
Analyst ratings (Buy, Hold, Sell) for AC Immune stock.
Analyst projections of the future price of AC Immune stock.
AC Immune Financial Performance
Revenues and expenses
AC Immune Earnings Performance
Company profitability
Upcoming events
No upcoming events
AC Immune News
AllArticlesVideos
Funds containing AC Immune
Fund name | Fund size | $ACIU weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.